IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival

Clinical Cancer Research

Volumn 18, Issue 22, 2012, Pages 6110-6121

  Wainwright, Derek A ^a   Balyasnikova, Irina V ^a   Chang, Alan L ^a   Ahmed, Atique U ^a   Moon, Kyung Sub ^a   Auffinger, Brenda ^a   Tobias, Alex L ^a   Han, Yu ^a   Lesniak, Maciej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INDOLEAMINE 2,3 DIOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; LONG TERM SURVIVAL; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; REGULATORY T LYMPHOCYTE RECRUITMENT; TUMOR GROWTH; UPREGULATION;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; GLUCOCORTICOID-INDUCED TNFR-RELATED PROTEIN; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; PROGNOSIS; RNA, SMALL INTERFERING; T-LYMPHOCYTES, REGULATORY; UP-REGULATION;

EID: 84869232447     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2130     Document Type: Article

References (43)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl Jour Med 2005;352:987-96. (Pubitemid 40349501)
2. El Andaloussi A, Lesniak MS. An increase in CD4+CD25+FOXP3+regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol 2006;8:234-43. (Pubitemid 46542648)
3. El Andaloussi A, Han Y, Lesniak MS. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 2006;105:430-7. (Pubitemid 44358755)
4. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006;66:3294-302.
5. Wainwright DA, Sengupta S, Han Y, Lesniak MS. Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro Oncol 2011;13:1308-23.
6. Wainwright DA, Sengupta S, Han Y, Ulasov IV, Lesniak MS. The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma. PLoS One 2010;5:e15390.
7. Crane CA, Ahn BJ, Han SJ, Parsa AT. Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol 2012;14:584-95.
8. James CD. Stimulating anti-tumor immune response: the problem of regulatory T-cells. Neuro Oncol 2011;13:1261.
9. Humphries W, Wei J, Sampson JH, Heimberger AB. The role of tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurg Clin Nor Amer 2010;21:125-37.
10. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002;3: 135-42. (Pubitemid 34141443)
11. Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M, et al. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother 2007;56:48-59. (Pubitemid 44812446)
12. Sakaguchi S. The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery. J Clin Invest 2003;112:1310-2. (Pubitemid 38057683)
13. Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 2008;57:123-31. (Pubitemid 350043644)
14. Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, et al. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 2011;118:4853-62.
15. Fujiwara M, Shibata M, Watanabe Y, Nukiwa T, Hirata F, Mizuno N, et al. Indoleamine 2,3-dioxygenase. Formation of L-kynurenine from L-tryptophan in cultured rabbit fineal gland. J Biol Chem 1978;253: 6081-5. (Pubitemid 9014249)
16. Miyazaki T, Moritake K, Yamada K, Hara N, Osago H, Shibata T, et al. Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. J Neurosurg 2009;111:230-7.
17. Avril T, Saikali S, Vauleon E, Jary A, Hamlat A, De Tayrac M, et al. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions. J Neuroimmunol 2010;225:22-33.
18. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999;189:1363-72. (Pubitemid 29227522)
19. Nakamura T, Shima T, Saeki A, Hidaka T, Nakashima A, Takikawa O, et al. Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci 2007;98:874-81. (Pubitemid 46691826)
20. Chung DJ, Rossi M, Romano E, Ghith J, Yuan J, Munn DH, et al. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 2009;114:555-63.
21. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007;117:2570-82. (Pubitemid 47494358)
22. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007;67:792-801. (Pubitemid 46192220)
23. Bulloch K, Miller MM, Gal-Toth J, Milner TA, Gottfried-Blackmore A, Waters EM, et al. CD11c/EYFP transgene illuminates a discrete network of dendritic cells within the embryonic, neonatal, adult, and injured mouse brain. J Comp Neurol 2008;508:687-710. (Pubitemid 351693557)
24. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Med 2003;9:1269-74. (Pubitemid 37279849)
25. National Cancer Institute: REMBRANDT home page. 2005 [http://rembrandt. nci.nih.gov], Accessed 2012 April 18th.
26. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011;478:197-203.
27. Alberati-Giani D, Malherbe P, Ricciardi-Castagnoli P, Kohler C, Denis- Donini S, Cesura AM. Differential regulation of indoleamine 2,3-dioxygenase expression by nitric oxide and inflammatory mediators in IFN-gamma-activated murine macrophages and microglial cells. J Immunol 1997;159:419-26. (Pubitemid 127493727)
28. Kwidzinski E, Bunse J, Aktas O, Richter D, Mutlu L, Zipp F, et al. Indolamine 2,3-dioxygenase is expressed in the CNS and downregulates autoimmune inflammation. FASEB 2005;19:1347-9. (Pubitemid 41113745)
29. Wang Y, Lawson MA, Kelley KW, Dantzer R. Primary murine microglia are resistant to nitric oxide inhibition of indoleamine 2,3-dioxygenase. Brain Behav Immun 2010;24:1249-53.
30. Vega EA, Graner MW, Sampson JH. Combating immunosuppression in glioma. Future Oncol 2008;4:433-42. (Pubitemid 351984094)
31. Wainwright DA, Nigam P, Thaci B, Dey M, Lesniak MS. Recent developments on immunotherapy for brain cancer. Expert Opin Emerg Drugs 2012;17:181-202.
32. Wintterle S, Schreiner B, Mitsdoerffer M, Schneider D, Chen L, Meyermann R, et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 2003;63:7462-7. (Pubitemid 37413489)
33. Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 2011;13:591-9.
34. Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol 2002;168:3771-6. (Pubitemid 34298376)
35. Saito K, Markey SP, Heyes MP. Chronic effects of gamma-interferon on quinolinic acid and indoleamine-2,3-dioxygenase in brain of C57BL6 mice. Brain Res 1991;546:151-4.
36. Kwidzinski E, Bunse J, Kovac AD, Ullrich O, Zipp F, Nitsch R, et al. IDO (indolamine 2,3-dioxygenase) expression and function in the CNS. Adv Exp Med Biol 2003;527:113-8. (Pubitemid 38197635)
37. Coe D, Begom S, Addey C, White M, Dyson J, Chai JG. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother 2010;59:1367-77.
38. Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-Cymmerman D, Kim SC, et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 2010;5:e10436.
39. Fotopoulou C, Sehouli J, Pschowski R, VON Haehling S, Domanska G, Braicu EI, et al. Systemic changes of tryptophan catabolites via the indoleamine-2,3-dioxygenase pathway in primary cervical cancer. Anticancer Res 2011;31:2629-35.
40. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 2010;185: 3190-8.
41. Joetham A, Ohnishi H, Okamoto M, Takeda K, Schedel M, Domenico J, et al. Loss of T regulatory cell suppression following signaling through glucocorticoid-induced tumor necrosis receptor (GITR) is dependent on c-Jun N-terminal kinase activation. J Bio Chem 2012;287:17100-8.
42. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011;17: 1094-100.
43. Soderlund J, Erhardt S, Kast RE. Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct. J Neuroinflamm 2010;7:44.